Catalog No.
PHM01301
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human HLA-DQA1 (Glu24-Glu216).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
DC-alpha, MHC class II DQA1, HLA class II histocompatibility antigen, DQ alpha 1 chain, DC-1 alpha chain, HLA-DQA1, HLA-DCA
Purification
Purified by antigen affinity column.
Accession
P01909
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Preformed anti-HLA DQA1/DQB1 DSA possibly responsible for graft failure in haploidentical stem cell transplantation., PMID:40530777
Annual Infliximab Monitoring After Treatment Optimization., PMID:40528082
Predictors of Immunogenicity and Loss of Response to ANTI-TNFα Therapy in Crohn Disease-A Systematic Review., PMID:40338684
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease., PMID:40315028
Computational Immunogenetic Analysis of Botulinum Toxin A Immunogenicity and HLA Gene Haplotypes: New Insights., PMID:40278680
Evaluating the Antigen and Eplet Accuracy of DQA1 Imputations With the HaploSFHI Two-Field HLA Typing Inference Tool., PMID:40269614
The Prospective Registry of MyositIS (PROMIS): I. Next-generation sequencing identifies HLA-DQA1 as a novel genetic risk of anti-MDA5 antibody-positive dermatomyositis., PMID:40246682
Transcriptomic signatures in peripheral CD4+T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation., PMID:40226614
Construction and evaluation of glucocorticoid dose prediction model based on genetic and clinical characteristics of patients with systemic lupus erythematosus., PMID:40186486
Identifying transcriptomic predictors of brodalumab response in psoriasis using CART analysis., PMID:40140063
SFRP2 mediates Epstein-Barr virus and bladder cancer risk: a Mendelian randomization study and colocalization analysis., PMID:40016549
Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs., PMID:39859084
Appraising the life-course impact of Epstein-Barr virus exposure and its genetic signature on periodontitis., PMID:39494826
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease., PMID:39423015
Does HLA-DQA1*05 carriage have a greater impact on the outcome of infliximab therapy for isolated small-bowel Crohn's disease?, PMID:39387318
Characterisation of the HLA-DQ alpha eplet 52SK targeting the DQA1*01 alleles family., PMID:39352216
Relationship between HLA-II Gene Polymorphisms and Immune Response in COVID-19 Survivors and Volunteers Vaccinated against This Infection., PMID:39340619
Genetic association of antinuclear antibodies with HLA in JIA patients: a Swedish cohort study., PMID:39187888
HLA-DQA1*05 Associates With Anti-Tumor Necrosis Factor Immunogenicity and Low Adalimumab Trough Concentrations in Inflammatory Bowel Disease Patients From the SERENE Ulcerative Colitis and Crohn's Disease Studies., PMID:39162746
HLA-DQA1*05 correlates with increased risk of anti-drug antibody development and reduced response to infliximab in Chinese patients with Crohn's disease., PMID:39055374
HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease., PMID:38937958
Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation., PMID:38926732
Homozygosity in any HLA locus is a risk factor for specific antibody production: the taboo concept 2.0., PMID:38840925
Multiple polygenic risk scores can improve the prediction of systemic lupus erythematosus in Taiwan., PMID:38724181
Recurrence of Idiopathic Membranous Nephropathy in the Kidney Allograft: A Systematic Review., PMID:38672095
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study., PMID:38640937
The influence of HLA allele and haplotype on RhE alloimmunization among pregnant females in the Chinese Han population., PMID:38637118
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response., PMID:38575714
Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α., PMID:38476237
HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease., PMID:38425314
Influence of HLA-DQA1*05 on the loss of response to anti-TNF treatment in inflammatory bowel disease. Spanish cohort of real clinical practice., PMID:38266819
Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis., PMID:38219222
The genome-wide association study of serum IgE levels demonstrated a shared genetic background in allergic diseases., PMID:38199299
Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis., PMID:38059274
HLA-DQA1*05 Not Associated With Ustekinumab Loss of Response and Antidrug Antibodies in Ulcerative Colitis and Crohn's Disease Patients., PMID:38029420
Investigating associations between HLA DQA1 ~ DQB1 haplotypes, H. pylori infection, metaplasia, and anti-CagA IgA seropositivity in a Turkish gastritis cohort., PMID:37979046
Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies., PMID:37769433
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis., PMID:37699653
Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease., PMID:37695555
HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers., PMID:37572797
Clinical Predictive Value of Phospholipase A2 Receptor Gene Polymorphism Combined with Subclass of Immunoglobulin G in Renal Tissues for Membranous Nephropathy., PMID:37535917
HLA class II antigens in Croatian patients with pemphigus vulgaris and their correlation with anti-desmoglein antibodies., PMID:37529044
HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients., PMID:37462462
HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn's disease patients., PMID:37460671
Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China., PMID:37359544
The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab., PMID:37314124
A Genetic Risk Score Distinguishes Different Types of Autoantibody-Mediated Membranous Nephropathy., PMID:37090184
Validation of a rapid HLA-DQA1*05 pharmacogenomics assay to identify at-risk resistance to anti-tumor necrosis factor therapy among patients with inflammatory bowel disease., PMID:37086490
Anti-LGI1 encephalitis: A family affair., PMID:37037125
One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study., PMID:37016150
For research use only. Not for human or drug use.
